|
Hypertensive disease
|
0.200 |
GeneticVariation
|
group |
BEFREE |
The most common adverse reactions are: gastrointestinal (COX1) which have declined over time with the emergence of more COX1 sparing drugs and gastroprotection; renal, with an impact on renal function and sodium extraction that is associated with hypertension, heart failure exacerbation, and stress-related renal failure; allergic skin reactions; increased transaminases and acute liver injury which may be idiosyncratic or immunoallergic; increased risk of acute coronary syndromes, initially associated with high-dose long-term use of COX2 specific inhibitors in controlled clinical trials, though more recently there have been indications from poorly controlled observational studies that they could occur with most NSAIDs.
|
30477749 |
2019 |
|
Hypertensive disease
|
0.200 |
Biomarker
|
group |
BEFREE |
This work also warrants an evaluation of high-dose aspirin and COX-2 inhibitor therapy in sufferers of inflammatory conditions who are already at increased risk for cardiovascular disease.-Khan, S. I., Shihata, W. A., Andrews, K. L., Lee, M. K. S., Moore, X.-L., Jefferis, A.-M., Vinh, A., Gaspari, T., Dragoljevic, D., Jennings, G. L., Murphy, A. J., Chin-Dusting, J. P. F. Effects of high- and low-dose aspirin on adaptive immunity and hypertension in the stroke-prone spontaneously hypertensive rat.
|
30156911 |
2019 |
|
Hypertensive disease
|
0.200 |
AlteredExpression
|
group |
BEFREE |
Hence, overexpression of YAP in endothelial cells enhanced the mRNA and protein levels of COX-2 and mPGES-1 and reversed the endothelial dysfunction and hypertension in <i>Tie2Cre-Raptor</i><sup>
|
31378107 |
2019 |
|
Hypertensive disease
|
0.200 |
Biomarker
|
group |
BEFREE |
These results showed that LMAE prevents Ang II-induced hypertension and vascular dysfunction through a reduction of oxidative stress linked to COX-2 and NOX-2 pathway and inhibition of calcium entry.
|
31183001 |
2019 |
|
Hypertensive disease
|
0.200 |
AlteredExpression
|
group |
BEFREE |
Therefore, RMIC COX-2 expression plays a crucial role in renal handling water and sodium homeostasis, preventing salt-sensitive hypertension and maintaining structural integrity of papilla.
|
30354807 |
2018 |
|
Hypertensive disease
|
0.200 |
Biomarker
|
group |
BEFREE |
These findings support oxylipins, particularly the ARA LOX-derived, in blood pressure control and indicate that pharmacologic inhibition of COX-2 has effects on LOX and CYP450 ARA metabolism that contribute to hypertension in some patients.
|
29698447 |
2018 |
|
Hypertensive disease
|
0.200 |
Biomarker
|
group |
BEFREE |
Site-specific inhibition of COX-2 in the renal medulla of Sprague-Dawley rats causes sodium retention and salt-sensitive hypertension.
|
27814606 |
2017 |
|
Hypertensive disease
|
0.200 |
Biomarker
|
group |
BEFREE |
However, the simultaneous inhibition of COX-2 in the vasculature translates into a prothrombotic phenotype and promotes hypertension and heart failure.
|
28569569 |
2017 |
|
Hypertensive disease
|
0.200 |
Biomarker
|
group |
BEFREE |
The data underscore the preferential capacity of selective COX-2 inhibition by celecoxib to mitigate CSA hypertension and consequent alterations in cardiac performance and autonomic balance.
|
28054752 |
2017 |
|
Hypertensive disease
|
0.200 |
Biomarker
|
group |
BEFREE |
However, the inhibition of COX-1 in cells of the gastrointestinal (GI) system and COX-2 in vascular cells translates into increased risk of serious GI adverse events and atherothrombosis and hypertension, respectively.
|
23953622 |
2014 |
|
Hypertensive disease
|
0.200 |
Biomarker
|
group |
BEFREE |
This BMP4/ROS/COX-2 cascade is important in the maintenance of endothelial dysfunction in hypertension.
|
20724703 |
2010 |
|
Hypertensive disease
|
0.200 |
AlteredExpression
|
group |
BEFREE |
Pulmonary and cardiorenal cyclooxygenase-1 (COX-1), -2 (COX-2), and microsomal prostaglandin E synthase-1 (mPGES-1) and -2 (mPGES-2) expression in a hypertension model.
|
17641732 |
2007 |
|
Hypertensive disease
|
0.200 |
Biomarker
|
group |
BEFREE |
COX-2 inhibitors may also exacerbate preexisting hypertension or interfere with other antihypertensive drugs.
|
15892676 |
2005 |
|
Hypertensive disease
|
0.200 |
Biomarker
|
group |
HPO |
|
|
|